RT Journal Article
T1 Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson's disease patients.
A1 Zago, Elisa
A1 Dal Molin, Alessandra
A1 Dimitri, Giovanna Maria
A1 Xumerle, Luciano
A1 Pirazzini, Chiara
A1 Bacalini, Maria Giulia
A1 Maturo, Maria Giovanna
A1 Azevedo, Tiago
A1 Spasov, Simeon
A1 Gómez-Garre, Pilar
A1 Periñán, María Teresa
A1 Jesús, Silvia
A1 Baldelli, Luca
A1 Sambati, Luisa
A1 Calandra-Buonaura, Giovanna
A1 Garagnani, Paolo
A1 Provini, Federica
A1 Cortelli, Pietro
A1 Mir, Pablo
A1 Trenkwalder, Claudia
A1 Mollenhauer, Brit
A1 Franceschi, Claudio
A1 Liò, Pietro
A1 Nardini, Christine
A1 PROPAG-AGEING Consortium, 
AB Advanced age represents one of the major risk factors for Parkinson's Disease. Recent biomedical studies posit a role for microRNAs, also known to be remodelled during ageing. However, the relationship between microRNA remodelling and ageing in Parkinson's Disease, has not been fully elucidated. Therefore, the aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson's Disease within the ageing framework. We employed Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson's Disease (recently diagnosed, drug-naïve) and healthy ageing (centenarians) plus healthy controls, age-matched with Parkinson's Disease patients. Potential microRNA candidates markers, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson's Disease patients, and healthy siblings of Parkinson's Disease patients at higher genetic risk for developing the disease. While we did not find evidences of microRNAs co-regulated in Parkinson's Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early Parkinson's Disease patients. Moreover, interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson's Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early Parkinson's Disease, robustly confirmed across a variety of analytical and experimental analyses. These promising results ask for further research to unveil the functional details of the involvement of hsa-mir144-3p in Parkinson's Disease.
YR 2022
FD 2022-01-25
LK http://hdl.handle.net/10668/19581
UL http://hdl.handle.net/10668/19581
LA en
DS RISalud
RD Apr 10, 2025